Angiopoietin‐2 levels as a biomarker of cardiovascular risk in patients with hypertension

Abstract

Among patients with hypertension, raised levels of Ang-2 were predictive of MI, and further study is warranted to evaluate the use of this biomarker in CVD management, risk stratification, and prevention.

Renin inhibition mitigates anti-angiogenesis in spontaneously hypertensive rats

“…Lee et al [18] demonstrated that angiopoietin-1 prevents hypertension and target organ damage. Furthermore, elevated angiopoietin-2 levels have been described as biomarkers of cardiovascular risk in patients with hypertension [19].…”

Angiopoietin-2 promoter haplotypes confer an increased risk of stroke in a Chinese Han population

“…Although we still do not know whether elevated angiopoietin-2 levels are a cause or an effect of ACS and hypertension, increased angiopoietin-2 levels have been reported as a biomarker of cardiovascular risk (myocardial infarction, stroke and death) in patients with hypertension [25]. We, therefore, hypothesized that genetic variants of ANGPT2 (the gene encoding angiopoietin-2) would contribute to the susceptibility of stroke.…”

A Decline in Glomerular Filtration Rate Rather than Renal Arterial Stenotic Lesions, per se, Predicts Cardiovascular-Renal Events in Type 2 Diabetic Patients

“…15 We set up the hypothesis that, under conditions where RAAS is not only caused by RAAS (+) itself but also because of peripheral vascular disorders, intra-renal ischemia would increase, tubulointerstitial disorder has progressed, the level of eGFR would drop, and CVREs would increase as a result. In this longitudinal study, we clarified that RAAS (+) and a decline in eGFR are both independent risk factors for CVREs in diabetes mellitus patients; the latter being more powerful than the former.…”